CartilaGen
Developing drug-eluting bioactive materials to treat articular cartilage damage and osteoarthritis.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | $125k | Grant | |
| Total Funding | 000k | ||
Related Content
CartilaGen Inc., a biotechnology firm established in 2018, is focused on developing therapeutics for osteoarthritis and cartilage regeneration. The company was co-founded by Dr. Meni Wanunu, a seasoned entrepreneur with a background in biophysics and materials science from Northeastern University and Tufts University, and Dr. Ouro-Nimini M.D., a specialist in bone and cartilage regeneration. Dr. Wanunu's entrepreneurial journey includes founding another company, Lamina, showcasing his experience in translating scientific discoveries into commercial ventures. This background in biophysics and venture creation is central to CartilaGen's approach to developing novel treatment modalities.
The company's primary business revolves around the research and development of a proprietary injectable therapy designed to regenerate cartilage. This positions CartilaGen within the musculoskeletal and regenerative medicine markets, specifically targeting the millions of individuals affected by osteoarthritis. The core of its product offering is an off-the-shelf, acellular biomaterial that functions as a joint lubricant and promotes the regeneration of cartilage tissue. A key differentiator of this therapy is its potential to be administered through a simple, minimally invasive intra-articular injection in an outpatient setting, which contrasts with more complex and invasive surgical procedures like microfracture or autologous chondrocyte implantation.
CartilaGen's business model is typical of a preclinical-stage biotechnology company, centered on achieving developmental milestones to attract investment and potential partnership or acquisition by larger pharmaceutical companies. The company has secured funding through various channels, including a notable $3.4 million in seed financing and grants from the Department of Defense and the National Institute of Health (NIH). These funds are directed towards advancing their lead candidate through preclinical studies, with the goal of eventually obtaining regulatory approval for human trials. Successful animal studies have demonstrated that the treatment can regenerate hyaline cartilage, the durable tissue found in joints.
Keywords: osteoarthritis, cartilage regeneration, regenerative medicine, biotechnology, injectable therapy, musculoskeletal, biomaterials, preclinical, joint lubricant, biophysics